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Abstract
Greater inhibitory activity against Escherichia coli and levels of human b defensin (HBD)-2 in genital tract
secretions predicted HIV acquisition in women in the HPTN 035 trial. We investigated whether higher levels of E.
coli inhibitory activity and antimicrobial peptides in cervicovaginal lavage (CVL) samples predicted HIV ac-
quisition in women in the CAPRISA 002 Acute Infection Study. E. coli inhibitory activity and antimicrobial
peptides were quantified in CVL from a subset of CAPRISA 002 participants who did not seroconvert (n = 39) and
from seroconverting women prior to infection (n = 17) and during acute infection (n = 11). Women who acquired
HIV had significantly greater preinfection CVL E. coli inhibitory activity ( p = 0.01) and HBD-1 levels ( p = 0.02)
compared to women who remained uninfected. Preinfection E. coli inhibitory activity remained significantly
associated with seroconversion following adjustment for the presence of bacterial vaginosis (OR 1.45; 95% CI
1.07, 1.97). Partial least squares discriminant analysis confirmed that preinfection CVL E. coli inhibitory activity,
together with higher CVL concentrations of HBD-1 and secretory leukocyte protease inhibitor, distinguished
seroconverters from nonseroconverters with 67% calibration accuracy. CVL concentrations of human neutrophil
peptides (HNP) 1–3 increased significantly with acute infection ( p = 0.001) and correlated with plasma viral set
point (r = 0.66, p = 0.03). E. coli inhibitory activity in genital tract secretions could provide a biomarker of HIV
risk. The correlation between HNP 1–3 and viral set point merits further investigation of the relationship between
mucosal inflammation during early HIV infection and disease progression.
Introduction
The ability of female genital secretions (FGS) toinhibit Escherichia coli growth in vitro may reflect
contributions from molecules secreted by epithelial and im-
mune cells, such as defensins and secretory leukocyte pro-
tease inhibitor (SLPI), and molecules secreted by the genital
tract microbiota.1–5 However, the clinical relevance of E. coli
inhibitory activity and the in vivo role of antimicrobial pep-
tides in preventing genital tract infections and HIV are not
well defined. Antimicrobial peptides such as defensins and
cathelicidins may paradoxically increase the risk of HIV
acquisition, transmission, and disease progression by pro-
moting mucosal inflammation and target cell recruitment to the
genital mucosa.6 Higher FGS concentrations of human neu-
trophil peptides (HNP) 1–3 and the cathelicidin LL-37 were
independently associated with increased risk of HIV acquisi-
tion in a cohort of female sex workers in Kenya; it was hy-
pothesized that higher concentrations of HNP 1–3 and LL-37
potentiated mucosal inflammation and target cell recruitment.7
In a substudy of the HPTN 035 trial, in which women at
risk for HIV seroconversion were randomized to receive one
of two topical HIV preexposure prophylaxis products (Buf-
ferGel or PRO 2000), placebo gel, or no gel, detectable
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human b defensin (HBD)-2 and higher E. coli inhibitory
activity in FGS were associated with increased risk of HIV
seroconversion [HBD-2 odds ratio (OR) 2.39; 95% (CI) 1.29,
4.41 and E. coli OR 1.22; 95% CI 1.04, 1.43].8 However,
samples were available from only eight seroconverting wo-
men from the HPTN 035 trial substudy, and plasma viral set
point data were not available to assess the relationship be-
tween E. coli inhibitory activity, antimicrobial peptides, and
HIV progression.
The CAPRISA 002 Acute Infection Study, a prospective,
observational study of uninfected women at high risk for HIV
infection in KwaZulu-Natal, South Africa, reported that FGS
inflammatory cytokine concentrations during acute infection
were associated with higher viral set point and faster CD4+ T
cell depletion at 12 months postinfection.9–11 While these
studies suggested that genital inflammatory cytokine markers
predicted more rapid HIV disease progression, they did not
investigate antimicrobial peptide profiles or E. coli inhibitory
activity. The objective of this study was to investigate the
relationship between HIV acquisition risk and FGS E. coli
inhibitory activity and antimicrobial peptides among a subset
of women who participated in the CAPRISA 002 Acute In-
fection Study. Furthermore, we investigated whether FGS
E. coli inhibitory activity and antimicrobial peptide concen-
trations were associated with plasma viral load set point, a
correlate of rate of HIV disease progression.
Materials and Methods
Study subjects
This study was approved by the University of KwaZulu-
Natal and the University of Cape Town Ethics Committees
and by the Albert Einstein College of Medicine Institutional
Review Board. A subset of women who participated in the
CAPRISA 002 Acute Infection Study who had available
CVL samples was included in this study.9 CAPRISA 002
participants attended monthly follow up visits for a maxi-
mum of 24 months. CVL (10 ml normal saline wash) was
collected at enrollment into CAPRISA 002 and following
HIV acquisition at the earliest time point when HIV infection
was diagnosed.9 Time of HIV infection in the CAPRISA 002
Acute Infection Study was defined as the midpoint between
the last negative HIV antibody test and the first positive an-
tibody test or as 14 days prior to the first detectable plasma
HIV-1 RNA on the same day as a negative HIV antibody test.
Plasma viral load set point was defined as the moving average
viral load closest to 52 (47–55) weeks postinfection.12
The primary objective of this study was to compare CVL
E. coli inhibitory activity and antimicrobial peptide concentra-
tions between preinfection samples from women who acquired
HIV and samples from women who remained seronegative.
The number of available samples was insufficient to allow for
matching of participants based on clinical variables. CVL
samples were available from 17 seroconverting women at a
median of 41 weeks preinfection [interquartile range (IQR)
16.5–69] and from 39 nonseroconverting women within 4
months of enrollment. Nonseroconverting women remained
HIV negative for the full duration (24 months) of follow-up.
A secondary objective was to evaluate CVL E. coli inhibitory
activity and antimicrobial peptide concentrations during
acute infection and to identify potential associations between
these variables and plasma viral load set point. CVL samples
were available from 11 of the 17 seroconverting women at the
time of acute infection [median 5 (IQR 5–7) weeks postin-
fection].
Study participants were screened for sexually transmitted
infections (STI) as previously described.13 Bacterial vaginosis
(BV) was defined as a Nugent score greater than seven. Herpes
simplex virus (HSV)-1,2 DNA was detected from vaginal
swabs by real-time multiplex polymerase chain reaction (M-
PCR).14 CVL HIV-1 RNA was quantified using Nuclisens
Easyq HIV-1 (version 1.2) (bioMerieux, Inc., Durham, NC).
Plasma HIV-1 RNA was quantified using COBAS Amplicor
HIV-1 Monitor version 1.5 or COBAS Ampliprep/COBAS
TaqMan 48 Analyser (Roche Diagnostics, Branchburg, NJ),
and CD4+ T cell counts (cells/ll) were quantified from blood
by FACSCalibur (BD, Franklin Lakes, NJ).
Evaluation of CVL E. coli inhibitory activity and soluble
immune mediators
Inhibitory activity against E. coli was quantified from CVL
using a colony-forming unit (cfu) reduction assay.1 E. coli
(ATCC strain 438227) was grown overnight to a concentra-
tion of approximately 109 cfu/ml. Bacteria (3 ll) were com-
bined with CVL (27 ll) or control buffer. The mixture was
incubated at 37C for 2 h and then diluted in buffer to yield
800–1,000 colonies on control plates before plating on agar
enriched with trypticase soy broth. Plates were incubated
overnight and colonies were counted with ImageQuant TL
v2005. All CVL samples were tested in duplicate. The per-
cent inhibition of E. coli was calculated relative to the
number of colonies formed on control plates.
Protein concentration from CVL was assessed by Micro-
BCA assay (Thermo Fisher Scientified, Rockford, IL). HBD-
1, -2, and -3 (Alpha Diagnostics, San Antonio, TX), HNP 1–3
(HyCult Biotechnology, Uden, The Netherlands), and SLPI
(R & D Systems, Minneapolis, MN) were quantified by
ELISA.
Statistical analyses
Analyses were performed using GraphPad Prism Version 5
(GraphPad Software, San Diego, CA) and SAS Version 9.2
(SAS Inc., Cary, NC). Concentrations of protein, defensins, and
SLPI were log-transformed to reduce skewness. Continuous
variables were compared between nonseroconverters and ser-
oconverters by t-test. Continuous variables were then compared
between preinfection and acute time points for seroconverting
women by the Wilcoxon signed-rank test. Categorical variables
were analyzed by chi-squared or Fisher’s exact tests. Paired
categorical data were analyzed by McNemar’s tests. Spear-
man’s correlation coefficients were calculated to assess po-
tential associations between continuous variables. All tests
for statistical significance were two-sided, and p values < 0.05
were considered significant. Logistic regression models were
used to assess the effects of variables identified in univariate
analysis on risk of seroconversion.
Partial least squares discriminant analysis (PLSDA) was
used to evaluate the antimicrobial peptide and E. coli inhib-
itory activity profiles that best distinguished between ser-
oconverters and nonseroconverters.15,16 PLSDA utilizes
covariance to identify linear combinations of independent
variables (latent variables) that best differentiate between
groups of interest. Every participant sample was assigned a
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score, which was then visualized in the latent variable space
(score plots). Latent variable loadings (loadings plots) were
then used to identify multivariate combinations of individual
variables associated with seroconversion. To reduce the risk of
overfitting, only markers with a variable importance projection
(VIP) score of >1 were included. All data were normalized with
mean centering and variance scaling. Cross-validation was
performed by iteratively excluding subsets of data in groups of
four to five during model calibration, then using excluded data
samples to test model predictions. Orthogonal signal correction
was used to improve model interpretability.
Results
Description of study subjects
The women who contributed samples to this study were all
urban, Zulu-speaking women from KwaZulu-Natal, South
Africa. Demographic details of the full cohort were previously
published.9 The prevalence of BV by Nugent’s score was
similarly high between seroconverters at the preinfection time
point (n = 17) and nonseroconverters (n = 39) (64.7% vs.
61.5%; p = 0.82) (Table 1). The median Nugent scores [7 (IQR
5–8) vs. 8 (IQR 3–9); p = 0.84] and the proportions of women
utilizing injectable long-acting hormonal contraception (29.4%
vs. 25.6%, respectively; p = 0.75) were also similar between
seroconverters and nonseroconverters (Table 1). None of the
women reported use of oral contraceptive pills. The proportions
of women with HSV-2 seropositivity, chlamydia, gonorrhea,
or trichomoniasis did not differ significantly between pre-
infection seroconverters and nonseroconverters (Table 1).
HSV DNA was not detected in preinfection seroconverter
vulvovaginal swabs but was detected in four swabs from
nonseroconverters ( p = 0.30).
For the 11 seroconverting women who had CVL available at
both the preinfection and acute infection time points, the me-
dian Nugent score was eight for both time points ( p = 0.22),
and the proportions of women with BV did not differ signifi-
cantly (72.7% vs. 90.9 %, respectively; p = 0.50). One woman
was diagnosed with chlamydia preinfection, two women were
diagnosed with trichomoniasis preinfection, and no women
were diagnosed with chlamydia or trichomoniasis at the acute
infection time point ( p = 1.0 for chlamydia, p = 0.47 for
trichomoniasis). Although no women at the preinfection time
point had gonorrhea, five women had gonorrhea during their
acute infection visit ( p = 0.04). Ten of the 11 women were
HSV-2 seropositive at the preinfection time point, and all 11
women were HSV-2 seropositive by the acute infection
time point ( p = 1.0); no women had detectable HSV shedding.
The median plasma HIV-1 viral load at acute infection was
360,000 copies/ml (IQR 41,600–621,000), and the median
CD4+ T cell count was 435 cells/ll (IQR 201–974). The me-
dian plasma viral load set point at 52 weeks postinfection was
Table 1. Distribution of Subject Characteristics and Logistic Regression Estimate





(n = 39) p value
Injectable hormonal contraceptive use, number positive (%) 5 (29.4) 10 (25.6) 0.75
Nugent score (median, IQR) 7 (5–8) 8 (3–9) 0.84
Bacterial vaginosis,2 number positive (%) 11 (64.7) 24 (61.5) 0.82
Herpes simplex virus-2 IgG, number positive (%) 15 (88.2) 34 (87.2) 1.0
Chlamydia trachomatis NAAT, number positive (%) 1 (5.9) 3 (7.7) 1.0
Neisseria gonorrhoeae NAAT, number positive (%) 0 (0) 2 (5.1) 1.00
Triahamonas vaginalis NAAT, number positive (%) 4 (23.5) 8 (20.5) 1.00
% Inhibition of Escherichia coli (mean – SD) 54.44 – 27.99 (n = 16) 34.11 – 17.92 (n = 38) 0.01
Total protein3 (mean – SD) 2.39 – 0.33 2.33 – 0.34 (n = 38) 0.56
SLPI3 (mean – SD) 5.4 – 0.63 5.17 – 0.54 0.16
HNP 1–33 (mean – SD) 4.29 – 0.76 4.19 – 0.59 0.58
HBD-13 (mean – SD) 3.39 – 0.4 3.1 – 0.42 0.02
HBD-23 (mean – SD) 3.48 – 0.95 3.72 – 0.6 0.25
HBD-33 (mean – SD) 2.93 – 0.49 2.85 – 0.46 0.56




Bacterial vaginosis4 1.5 0.36–6.38 0.58
% Inhibition of E. coli5 1.45 1.07–1.97 0.02
HBD-16 4.43 0.82–23.83 0.08
1Baseline characteristics of seroconverting subjects (prior to infection) and nonseroconverting subjects.
2Diagnosis by Nugent’s score.
3Quantified from cervicovaginal lavage fluid and expressed as log10 (lg/ml) units (total protein) or as log10 (pg/ml) units (SLPI, HNP 1–3,
HBD 1–3).
4Presence or absence of bacterial vaginosis by Nugent’s score.
5Estimated increased risk of HIV acquisition for every 10% increase in bactericidal E. coli activity.
6Estimated increased risk of HIV acquisition for every log10 unit increase in concentration of HBD-1.
IQR, interquartile range; NAAT, nucleic acid amplification test; SD, standard deviation; SLPI, secretory leukocyte protease inhibitor;
HNP, human neutrophil peptides; HBD, human b defensin.
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56,033 copies/ml (IQR 3,162–195,133). In CVL, HIV-1 RNA
was detected in 4/10 (40%) acutely infected samples (one
sample was not available for testing) with a median viral load
of 1,110 copies/ml (IQR 199.8–1,614).
Preinfection E. coli inhibitory activity was higher
in seroconverters than nonseroconverters
and was associated with HIV acquisition risk
Preinfection mean CVL E. coli inhibitory activity was
significantly higher in seroconverters compared to non-
seroconverters [54.4% – standard deviation (SD) 28.0 vs.
34.1% – 17.9; p = 0.01] (Table 1). In addition, mean CVL
concentrations of HBD-1 were significantly higher in ser-
oconverters compared to nonseroconverters [3.4 log10 (pg/
ml) units – SD 0.4 vs. 3.1 – 0.4; p = 0.02]. There were no
significant differences in CVL concentrations of protein,
HBD-2, HBD-3, HNP 1–3, or SLPI between seroconverters
and nonseroconverters.
In a logistic regression model that adjusted for the presence
of BV, the odds of HIV acquisition increased 1.45-fold for
every 10% increase in E. coli inhibitory activity (OR 1.45;
95% CI 1.07, 1.97; p = 0.02) (Table 1). Each log10 unit in-
crease in CVL HBD-1 concentration was associated with a
4.43 times greater risk of HIV acquisition (OR 4.43; 95% CI
0.82, 23.83; p = 0.08); however, this result was of borderline
statistical significance.
Higher CVL E. coli inhibitory activity, HBD-1, and SLPI
were associated with HIV seroconversion by PLSDA
PLSDA was used to determine which combinations of pre-
infection variables were most useful for classifying women
as potential HIV seroconverters or nonseroconverters. CVL
E. coli inhibitory activity, together with concentrations of SLPI
and HBD-1, classified women as those who subsequently ser-
oconverted versus those who did not with 67% calibration ac-
curacy and 64% cross-validation accuracy (Fig. 1a). The first
two latent variables in this model captured 86% of the variance
in the data set. Examination of the loadings plot indicated that
latent variable 1 (LV1) best differentiated the preinfection group
from those who remained uninfected, and correspondingly the
seroconverter (negative scores on LV1; Fig. 1a) profile was
associated with elevated CVL E. coli inhibitory activity, SLPI,
and HBD-1 (all negatively loaded on LV1, Fig. 1b). The com-
bined model including CVL E. coli inhibitory activity, SLPI, and
HBD-1 performed slightly better in classifying women as ser-
oconverters or nonseroconverters than a model that used E. coli
inhibition alone (32% calibration error for combined vs. 39%
calibration error for E. coli inhibition alone, data not shown).
Acute HIV infection was associated with increased
human neutrophil peptides but decreased SLPI
concentrations in CVL
Mean CVL HNP 1–3 levels increased significantly from
preinfection to acute infection [4.2 log10 (pg/ml) units – SD 0.9
vs. 5.3 – 0.7; p = 0.001] (Fig. 2), while mean concentrations of
SLPI in CVL were significantly lower during acute infection
FIG. 1. Scores and loadings plots for partial least squares discriminant analysis (PLSDA) model. (a) A PLSDA model
using cervicovaginal lavage (CVL) E. coli inhibition and concentrations of human b defensin (HBD)-1 and secretory
leukocyte protease inhibitor (SLPI) in samples prior to HIV infection classified women as seroconverters or non-
seroconverters with 67% accuracy (red: women who acquired HIV; blue: women who remained uninfected). (b) Latent
variable 1 separated women who acquired HIV from those who remained uninfected. E. coli inhibition, HBD-1, and SLPI
were all negatively loaded on LV1, suggesting they were positively associated with HIV acquisition.
FIG. 2. Comparison of Nugent scores, cervicovaginal lavage
(CVL) E. coli inhibitory activity, and CVL concentrations of
secretory leukocyte protease inhibitor (SLPI), human neutro-
phil peptides (HNP) 1–3, human b defensin (HBD)-2, HBD-1,
and protein from 11 seroconverting women preinfection and
during acute infection. CVL E. coli inhibitory activity was
unavailable for one woman at the preinfection time point.
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compared to preinfection [4.8 log10 (pg/ml) units – SD 0.76 vs.
5.5 – 0.54; p = 0.02]. Mean CVL E. coli inhibitory activity
increased from preinfection to acute infection, but this increase
did not reach statistical significance (56.1% – SD 35.6 vs.
74.6% – 10.1; p = 0.13). Mean Nugent scores and levels of
protein, HBD-2, and HBD-1 did not differ significantly be-
tween preinfection and acute infection (Fig. 2). Samples were
not available for HBD-3 quantification in the acute infection
group. Five women in the acute infection group had gonorrhea
at the time of sample collection. However, CVL mean E. coli
inhibition and concentrations of protein, SLPI, and defensins
did not differ significantly between acute infection samples
collected from women with and without gonorrhea ( p > 0.05
for all, data not shown).
E. coli inhibitory activity and antimicrobial peptide
concentrations were elevated in acute infection CVL
samples with detectable HIV-1 RNA
Mean E. coli inhibitory activity (82.25% – SD 6.24 vs.
68.43 – 5.38; p = 0.003) and concentrations of HBD-1
(4.28 – SD 0.33 vs. 3.33 – SD 0.33; p = 0.002) and HBD-2
(4.18 – SD 0.36 vs. 2.92 – SD 0.36; p < 0.001) were signif-
icantly higher in the four acute infection CVL samples with
detectable HIV-1 RNA compared to the six samples with-
out detectable HIV-1 RNA (Table 2). Mean concentrations
of HNP 1–3 and SLPI were also higher in CVL samples
with detectable HIV-1 RNA, although these differences
were not significant.
CVL defensin concentrations during acute infection
correlated with E. coli inhibitory activity and plasma
viral load set point
CVL E. coli inhibitory activity at acute infection corre-
lated positively with CVL concentrations of protein (r = 0.71,
p = 0.02), HBD-1 (r = 0.61, p = 0.05), and HBD-2 (r = 0.91,
p = 0.001). A trend toward a positive correlation between CVL
E. coli inhibitory activity at acute infection and CVL concen-
trations of HNP 1–3 (r = 0.49, p = 0.13) and SLPI (r = 0.57,
p = 0.07) was observed. Of note, significant correlations be-
tween CVL E. coli inhibitory activity and antimicrobial peptides
were not detected in samples from nonseroconverting women or
in seroconverting women at the preinfection time point. Acute
infection CVL concentrations of HNP 1–3 correlated positively
and significantly with viral set point (r = 0.66, p = 0.03).
Discussion
In this study of women enrolled in the CAPRISA 002
study, higher E. coli inhibitory activity and HBD-1 in CVL
were associated with increased risk of HIV acquisition. These
results are consistent with the findings of a substudy of HPTN
035, in which higher levels of E. coli inhibitory activity and
HBD-2 in FGS were associated with a higher risk of HIV
acquisition among eight seroconverting women, and indicate
that E. coli inhibitory activity may provide a biomarker of
HIV acquisition risk.8
The precise mediators of E. coli inhibitory activity in FGS
have not yet been elucidated. It is likely that the relative
contributions from vaginal microbiota and host-derived sol-
uble immune mediators at the genital mucosa differ between
distinct populations of women. In a prior study of 99 U.S.
women who did not have an STI or BV and who were at low
risk for HIV acquisition, E. coli inhibitory activity did not
correlate with CVL concentrations of defensins and other
host-derived molecules.1 Instead, proteomic studies from five
participants with CVL inhibition >90% showed that this ac-
tivity was associated with surface proteins specific to Lac-
tobacillus crispatus and L. jensenii.1 Vaginal microbiota data
are not yet available for the women included in our study.
However, the high Nugent scores among participants in this
study, coupled with the observed correlations between de-
fensins and E. coli inhibitory activity during acute HIV in-
fection, suggest that among women with a paucity of
lactobacilli, E. coli inhibitory activity may represent defensin
influx and mucosal inflammation. The observed associations
between defensins, CVL E. coli inhibitory activity, and HIV
seroconversion merit further investigation in prospective
studies that utilize protein mass spectrometry of FGS to
identify the precise mediators that confer HIV risk.
We also used PLSDA to identify relationships between
CVL E. coli inhibitory activity and antimicrobial peptides
that were most associated with HIV seroconversion and
found that seroconversion was most associated with a mul-
tivariate profile that included higher CVL E. coli inhibition,
HBD-1, and SLPI. Moreover, we observed a trend toward
higher SLPI concentrations in acute infection CVL samples
with detectable HIV-1 RNA compared to samples without
detectable HIV-1 RNA. Taken alone, the weak association
between higher CVL concentrations of SLPI and HIV sero-
conversion and detectable HIV-1 RNA is somewhat sur-
prising. SLPI exerts activity against HIV in vitro,17 and prior
Table 2. Antimicrobial Peptide Concentrations in Cervicovaginal Lavage Fluid Samples
with Detectable or Nondetectable HIV RNA During Acute HIV Infection
Detectable HIV
RNA (n = 4)
Nondetectable
HIV RNA (n = 6) p value
CVL HIV RNA viral load (copies/ml), median (IQR) 1,110 (199.8–1,624)
% Inhibition of E. coli (mean – SD) 85.25 – 6.24 68.43 – 5.38 0.003
Total protein1 (mean – SD) 2.69 – 0.18 2.15 – 0.73 0.18
SLPI1 (mean – SD) 5.37 – 0.20 4.5 – 0.79 0.06
HNP 1–31 (mean – SD) 5.74 – 0.19 5.06 – 0.84 0.15
HBD-11 (mean – SD) 4.28 – 0.33 3.33 – 0.36 0.002
HBD-21 (mean – SD) 4.18 – 0.36 (n = 3) 2.92 – 0.36 < 0.001
1Quantified from CVL fluid and expressed as log10 (lg/ml) units (total protein) or as log10 (pg/ml) units (SLPI, HNP 1–3, HBD 1–3).
SLPI, secretory leukocyte protease inhibitor; HNP, human neutrophil peptides; HBD, human b defensin.
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studies have identified associations between lower SLPI
concentrations and HIV seroconversion risk in larger popu-
lations.18 It is possible that higher levels of HIV-1 RNA in the
genital tract may induce epithelial cell expression of SLPI,
and the association between higher SLPI levels preinfection
and HIV seroconversion risk could represent HIV-1-induced
expression of SLPI by epithelial cells in the setting of re-
peated HIV exposure from sexual partners.19
Although defensins have potent anti-HIV activity ex
vivo,20,21 we identified higher HBD-1 concentrations in pre-
infection seroconverters compared to nonseroconverters, and
acute infection CVL samples with detectable HIV-1 RNA
had significantly higher concentrations of HBD-1 and -2
relative to samples without detectable HIV-1 RNA. HBD-2
expression may be induced by inflammatory stimuli17,22 and
by HIV-1 Tat activation of NF-jB-dependent pathways.23
However, HBD-1 is thought to be expressed constitutively,
and its association with increased risk of HIV acquisition
requires further investigation. Our finding of higher genital
tract HNP 1–3 levels at acute infection could reflect recruit-
ment of degranulating neutrophils by IL-8, MIP-3a, and other
proinflammatory mediators24 that may promote activation of
NF-jB and recruitment of HIV target cells.6,25 The correla-
tion between CVL HNP 1–3 and plasma viral set point sug-
gests that concentrations of defensins at the genital mucosa
during acute HIV infection could impact long-term HIV
progression and underscores the relationship between mu-
cosal inflammatory cytokine profiles and viral set point de-
scribed in prior CAPRISA 002 studies.10,11
The limitations of this small study are that we do not have
detailed information about the vaginal microbiota, and white
blood cell quantification was not available from samples for
which Nugent scores were performed. There are several
important variables, such as sexual behaviors, intravaginal
practices, phase of menstrual cycle, and genital tract patho-
gens (other than those for which participants were tested) that
may have impacted our results. Moreover, the dilutional ef-
fect of CVL may have limited our ability to detect molecules
present in low concentrations. Despite these limitations, this
study describes a significant association between E. coli in-
hibitory activity and HIV acquisition risk. This inexpensive
and noninvasive assay may provide a feasible biomarker of
HIV seroconversion risk in populations of women with a
higher prevalence of subclinical or clinical BV, and the
combination of this biomarker with concentrations of SLPI
and defensins may increase predictive value. If validated in
larger studies, this assay may be useful to identify women
most in need of prevention strategies and to screen potential
subjects for HIV prevention studies. Identifying the host and
microbial mediators that contribute to this activity could also
inform the development of effective HIV preexposure pro-
phylaxis strategies.
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